血管抑肽(Angiopeptin)预防PTCA后及/或支架内再狭窄  

Angiopeptin For Prevention of Post-PTCA/In-Stent Restenosis in Coronary Artery

作　　者：王春宁[1] 

机构地区：[1]中国医学科学院中国协和医科大学心血管病研究所阜外医院,北京100037

出　　处：《心血管病学进展》2002年第6期333-337,共5页Advances in Cardiovascular Diseases

摘　　要：血管抑肽 (angiopeprin) ,一种人工合成的环八肽 ,生长抑素 (somatostatin)的类似物 ,在动物实验证实可抑制动脉损伤后的内膜增生、预防PTCA(经皮穿刺冠状动脉扩张成型术 )后再狭窄 ,然而 ,预防PTCA后再狭窄的临床试验则有不同的结果。我们简要复习了近年文献 ,讨论了血管抑肽在预防PTCA后及支架内再狭窄的作用 。Angiopeptin is a synthetic circle octopeptide(an anologue of somatostatin),which can inhibit intimal hyperplasia after artery injury and prevent restenosis after PTCA in animal studies.However,clinical trials of angiopeptin for prevention of restenosis after PTCA revealed different outcomes.We briefly reviewed references on angiopeptin in recent years,discussed the action of angiopeptin in prevention of restenosis after PTCA and in stent restenosis and analyzed the route and methodology of angiopeptin administered and the reasons for the outcomes of animal studies and clinical trials of angiopeptin for prevention of restenosis after PTCA and in stent restenosis.

关 键 词：PTCA 再狭窄 血管抑肽 生长抑素受体 冠状动脉成形术 

分 类 号：R541.4[医药卫生—心血管疾病]